← All trials
NCT05614037
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2022
- Primary completion
- Nov 20, 2022
- Completion date
- Dec 30, 2022
- First posted
- Nov 14, 2022
- Last posted
- Dec 6, 2022
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Overseas Pharmaceuticals, Ltd.Lead sponsor
- Guangzhou Kangqi Medical Technology Co., LTDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.